Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.13 Insider Own20.00% Shs Outstand11.27M Perf Week9.26%
Market Cap52.26M Forward P/E- EPS next Y-3.84 Insider Trans0.00% Shs Float9.09M Perf Month80.39%
Income-69.17M PEG- EPS next Q-0.92 Inst Own37.35% Short Float0.65% Perf Quarter208.72%
Sales0.00M P/S- EPS this Y39.04% Inst Trans-4.13% Short Ratio0.80 Perf Half Y105.82%
Book/sh6.77 P/B0.68 EPS next Y-7.50% ROA-58.35% Short Interest0.06M Perf Year17.65%
Cash/sh6.52 P/C0.71 EPS next 5Y- ROE-64.00% 52W Range1.04 - 4.95 Perf YTD145.32%
Dividend Est.- P/FCF- EPS past 5Y41.46% ROI-84.67% 52W High-7.07% Beta1.68
Dividend TTM- Quick Ratio11.49 Sales past 5Y0.00% Gross Margin- 52W Low342.31% ATR (14)0.35
Dividend Ex-Date- Current Ratio11.49 EPS Y/Y TTM-85.21% Oper. Margin0.00% RSI (14)73.87 Volatility9.49% 10.22%
Employees25 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price30.60
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-27.27% Payout- Rel Volume1.29 Prev Close4.56
Sales Surprise- EPS Surprise11.22% Sales Q/Q- EarningsNov 03 BMO Avg Volume73.43K Price4.60
SMA2029.02% SMA5070.40% SMA200104.86% Trades Volume94,391 Change0.88%
Date Action Analyst Rating Change Price Target Change
Jul-10-23Resumed Guggenheim Buy $22
Jun-04-21Initiated H.C. Wainwright Buy $40
Feb-17-21Initiated Oppenheimer Outperform $43
Oct-19-20Initiated Cowen Outperform $50
Jul-29-20Initiated Guggenheim Buy $50
Feb-28-24 08:00AM
Jan-31-24 07:30AM
Nov-30-23 08:30AM
Nov-03-23 09:43AM
08:00AM Loading…
Oct-23-23 08:00AM
Sep-20-23 08:30AM
Sep-05-23 07:30AM
Aug-03-23 08:00AM
May-15-23 08:00AM
May-04-23 08:00AM
May-02-23 08:00AM
Apr-28-23 08:00AM
Mar-08-23 08:00AM
Mar-01-23 08:00AM
08:00AM Loading…
Feb-02-23 08:00AM
Jan-30-23 08:00AM
Dec-01-22 08:00AM
Nov-03-22 08:00AM
Oct-24-22 08:35AM
Sep-06-22 08:00AM
Aug-09-22 08:00AM
Jun-21-22 08:00AM
May-26-22 05:11PM
May-17-22 08:00AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-11-22 09:55AM
Mar-24-22 08:00AM
10:00AM Loading…
Mar-23-22 10:00AM
Mar-09-22 07:30AM
Mar-08-22 05:50AM
Mar-02-22 08:00AM
Feb-01-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-08-21 11:15AM
Nov-04-21 08:00AM
Oct-25-21 04:45PM
Oct-12-21 07:00AM
Sep-17-21 04:05PM
Sep-13-21 07:00AM
Sep-09-21 10:31AM
Sep-07-21 08:00AM
Aug-05-21 08:00AM
Jul-07-21 08:00AM
Jun-22-21 07:30AM
Jun-10-21 08:00AM
May-13-21 08:00AM
May-06-21 07:30AM
Apr-23-21 07:00AM
Apr-19-21 04:09PM
Apr-12-21 11:12AM
Mar-30-21 07:01AM
Mar-11-21 07:30AM
Mar-10-21 08:00AM
Feb-04-21 08:00AM
Feb-02-21 08:00AM
Dec-16-20 11:07PM
Dec-07-20 04:30PM
Dec-03-20 07:00AM
Nov-24-20 07:00AM
Nov-12-20 07:15AM
Nov-11-20 07:00AM
Nov-04-20 07:00AM
Sep-28-20 03:12PM
Sep-22-20 08:13AM
Sep-21-20 04:01PM
Sep-08-20 07:00AM
Sep-02-20 05:49PM
Aug-03-20 07:00AM
Jul-28-20 07:00AM
Jul-24-20 07:00AM
Jul-03-20 06:34PM
Jul-02-20 07:59PM
Jun-02-20 04:05PM
May-26-20 08:30AM
May-13-20 08:00AM
May-11-20 08:38AM
May-05-20 04:05PM
Apr-02-20 07:00AM
Feb-11-20 08:00AM
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.